Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Other Operating Expenses: 2016-2025

Historic Other Operating Expenses for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to $28.1 million.

  • Tg Therapeutics' Other Operating Expenses rose 200.75% to $28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.0 million, marking a year-over-year increase of 152.01%. This contributed to the annual value of $38.5 million for FY2024, which is 172.35% up from last year.
  • Tg Therapeutics' Other Operating Expenses amounted to $28.1 million in Q3 2025, which was up 48.34% from $18.9 million recorded in Q2 2025.
  • Tg Therapeutics' Other Operating Expenses' 5-year high stood at $28.1 million during Q3 2025, with a 5-year trough of $2,000 in Q3 2022.
  • Over the past 3 years, Tg Therapeutics' median Other Operating Expenses value was $8.3 million (recorded in 2024), while the average stood at $10.5 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first tumbled by 99.32% in 2022, then skyrocketed by 261,700.00% in 2023.
  • Tg Therapeutics' Other Operating Expenses (Quarterly) stood at $210,000 in 2021, then slumped by 98.57% to $3,000 in 2022, then spiked by 261,700.00% to $7.9 million in 2023, then surged by 96.07% to $15.4 million in 2024, then soared by 200.75% to $28.1 million in 2025.
  • Its Other Operating Expenses stands at $28.1 million for Q3 2025, versus $18.9 million for Q2 2025 and $15.5 million for Q1 2025.